XENE confirms plans to submit its AZK new drug application this quarter, extending cash runway into 2029.
Xenon Pharmaceuticals announced it completed a pre-NDA meeting with the FDA and expects to file its AZK new drug application later this quarter. The submission follows successful regulatory discussions, keeping the company on track for its 2026 timeline.
Management reiterated operational funding through 2029, aligning with prior guidance. The AZK submission remains a key execution priority, with no changes to the company’s strategic outlook or financial projections.
Shares showed limited immediate reaction to the update, reflecting investor focus on upcoming regulatory milestones.